相关实验视频

Updated: Jun 9, 2025

Author Spotlight: High-Quality Quantum Dot Nanobeads for Sensitive Fluorescent Lateral Flow Immunoassays

Author Spotlight: High-Quality Quantum Dot Nanobeads for Sensitive Fluorescent Lateral Flow Immunoassays

Published on: June 28, 2024

口服活性碳量子点用于糖尿病

Gamze Camlik^1,2, Besa Bilakaya^1,2, Esra Küpeli Akkol³

¹Department of Pharmaceutical Technology, Faculty of Pharmacy, Biruni University, Istanbul 34015, Türkiye.

Pharmaceuticals (Basel, Switzerland)

|October 26, 2024

概括

与传统的甲胺相比,甲胺碳量子点 (MetCQDs) 在治疗大鼠II型糖尿病方面表现出更高的疗效,显著降低血糖水平并改善肝脏健康指标. 这些新型纳米粒子为糖尿病管理提供了潜在的治疗优势.

科学领域:

纳米技术纳米技术
材料科学材料科学材料科学
药理学药理学是指药理学的学科.

背景情况:

甲胺 (Met) 是一种用于治疗II型糖尿病的关键口服抗糖尿病药物.
碳量子点 (CQD) 提供了增强的生物可用性,透性和低细胞毒性.
合成了甲胺碳量子点 (MetCQDs),以改善甲胺的治疗特性.

研究的目的:

使用微波辅助方法从活性分子中合成MetCQDs.
为了描述合成的MetCQDs.
评估MetCQDs在糖尿病大鼠模型中的治疗疗效.

主要方法:

微波辅助合成的MetCQDs. 的微波辅助合成.
包括粒子大小,泽塔潜力和量子产量确定在内的表征.
在Streptozocin诱导的糖尿病Wistar白色老鼠体内疗效研究.

主要成果:

MetCQDs的粒子大小为9.02 ± 0.04 nm,量子产量为15.1 ± 0.045%.
在糖尿病老鼠中,MetCQDs显示出显著的血糖降低 (34.1-51.1%) .
组织病理学分析显示,在MetCQD治疗组中,肝脏健康指标得到改善.

结论:

MetCQDs显示了糖尿病管理的增强治疗潜力.
新的MetCQD配方可能会提高疗效,并可能减少副作用.
这些发现表明,对于抗糖尿病药物输送系统来说,这是一个有希望的新途径.

关键词:

碳量子点是指一个量子点.甲胺是一种甲胺.纳米技术是纳米技术.通过口服进行口服管理.第二种类型的糖尿病.

更多相关视频

Compact Quantum Dots for Single-molecule Imaging

Compact Quantum Dots for Single-molecule Imaging

Published on: October 9, 2012

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

相关概念视频

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Diabetes: Symptoms, Diagnosis, and Complications

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...